相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-world safety and effectiveness of elexacaf tor/tezacaf tor/ivacaf tor in people with cystic fibrosis: Interim results of a long-term registry-based study
Julie K. Bower et al.
JOURNAL OF CYSTIC FIBROSIS (2023)
Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial
Matthias Griese et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic
Shreya Patel et al.
PEDIATRIC PULMONOLOGY (2021)
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study
Patrick A. Flume et al.
LANCET RESPIRATORY MEDICINE (2021)
The future of cystic fibrosis care: a global perspective
Scott C. Bell et al.
LANCET RESPIRATORY MEDICINE (2020)
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Harry G. M. Heijerman et al.
LANCET (2019)
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
P. G. Middleton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles
Jennifer L. Taylor-Cousar et al.
ERJ OPEN RESEARCH (2019)
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Steven M. Rowe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Jennifer L. Taylor-Cousar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data
Gregory S. Sawicki et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Cystic fibrosis
Felix Ratjen et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
Kris De Boeck et al.
JOURNAL OF CYSTIC FIBROSIS (2014)
Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries
Alexandra L. Quittner et al.
THORAX (2014)
Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)
Edward F. McKone et al.
LANCET RESPIRATORY MEDICINE (2014)
Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis
Valerie Waters et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Bonnie W. Ramsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
CFTR function and prospects for therapy
John R. Riordan
ANNUAL REVIEW OF BIOCHEMISTRY (2008)
分享论文
